What is Zacks Research's Estimate for ALLO Q1 Earnings?

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Stock analysts at Zacks Research boosted their Q1 2025 EPS estimates for shares of Allogene Therapeutics in a note issued to investors on Wednesday, April 2nd. Zacks Research analyst R. Department now expects that the company will earn ($0.31) per share for the quarter, up from their prior forecast of ($0.37). The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Allogene Therapeutics' Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.26) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.40) EPS.

A number of other equities research analysts have also recently issued reports on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $10.00 target price on shares of Allogene Therapeutics in a report on Friday, March 14th. Canaccord Genuity Group reissued a "buy" rating and set a $14.00 price target on shares of Allogene Therapeutics in a research report on Friday, March 14th. Citizens Jmp raised Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 price objective for the company in a research report on Friday, March 14th. Finally, HC Wainwright reduced their target price on Allogene Therapeutics from $9.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, March 19th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $9.29.

Allogene Therapeutics Price Performance

NASDAQ ALLO traded up $0.08 on Monday, hitting $1.45. 2,175,704 shares of the stock were exchanged, compared to its average volume of 3,204,871. The company has a market capitalization of $315.03 million, a PE ratio of -0.93 and a beta of 0.99. The business's fifty day moving average is $1.75 and its 200 day moving average is $2.14. Allogene Therapeutics has a 52 week low of $1.23 and a 52 week high of $4.01.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.06.

Insider Transactions at Allogene Therapeutics

In other news, CEO David D. Chang sold 46,668 shares of Allogene Therapeutics stock in a transaction on Friday, March 14th. The stock was sold at an average price of $1.96, for a total transaction of $91,469.28. Following the completion of the sale, the chief executive officer now owns 5,276,569 shares of the company's stock, valued at approximately $10,342,075.24. This trade represents a 0.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Timothy L. Moore sold 14,746 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $25,215.66. Following the completion of the transaction, the insider now owns 250,713 shares in the company, valued at $428,719.23. This trade represents a 5.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 104,866 shares of company stock worth $194,461. Company insiders own 24.30% of the company's stock.

Institutional Trading of Allogene Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Intech Investment Management LLC bought a new position in shares of Allogene Therapeutics during the third quarter worth approximately $116,000. The Manufacturers Life Insurance Company grew its position in Allogene Therapeutics by 1.2% during the third quarter. The Manufacturers Life Insurance Company now owns 486,023 shares of the company's stock worth $1,361,000 after buying an additional 5,642 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Allogene Therapeutics by 541.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 46,374 shares of the company's stock worth $130,000 after acquiring an additional 39,145 shares during the period. EP Wealth Advisors LLC raised its holdings in Allogene Therapeutics by 125.6% in the 3rd quarter. EP Wealth Advisors LLC now owns 24,475 shares of the company's stock valued at $69,000 after acquiring an additional 13,625 shares in the last quarter. Finally, Zacks Investment Management acquired a new position in Allogene Therapeutics in the 3rd quarter valued at $1,446,000. Institutional investors and hedge funds own 83.63% of the company's stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).